Thérapie, 63 3 (2008) 187-229

Article's citations

Article cité par

La fonctionnalité Article cité par… liste les citations d'un article. Ces citations proviennent de la base de données des articles de EDP Sciences, ainsi que des bases de données d'autres éditeurs participant au programme strong>CrossRef Cited-by Linking Program. Vous pouvez définir une alerte courriel pour être prévenu de la parution d'un nouvel article citant " cet article (voir sur la page du résumé de l'article le menu à droite).

Article cité :

Cognitive Impairment in Schizophrenia: a Review of Developmental and Genetic Models, and Pro-cognitive Profile of the Optimised D₃ > D₂ Antagonist, S33138

Mark J. Millan, Mauricette Brocco

Thérapie, 63 3 (2008) 187-229

Publié en ligne : 2008-08-23

DOI: https://doi.org/10.2515/therapie:2008041

Citations de cet article :

Kevin Butler, Bernard Le Foll and Patricia Di Ciano
60 203 (2022)
DOI: 10.1007/7854_2022_392
Voir cet article

Sebastiano Alfio Torrisi, Federica Geraci, Gabriella Contarini, Salomone Salomone, Filippo Drago and Gian Marco Leggio
60 133 (2022)
DOI: 10.1007/7854_2022_326
Voir cet article

Enhancing cognition through pharmacological and environmental interventions: Examples from preclinical models of neurodevelopmental disorders

Lorenzo Morè, Julie C. Lauterborn, Francesco Papaleo and Riccardo Brambilla
Neuroscience & Biobehavioral Reviews 110 28 (2020)
DOI: 10.1016/j.neubiorev.2019.02.003
Voir cet article

Dual-acting agents for improving cognition and real-world function in Alzheimer’s disease: Focus on 5-HT6 and D3 receptors as hubs

Mark J. Millan, Anne Dekeyne, Alain Gobert, Mauricette Brocco, Clotilde Mannoury la Cour, Jean-Claude Ortuno, David Watson and Kevin C.F. Fone
Neuropharmacology 177 108099 (2020)
DOI: 10.1016/j.neuropharm.2020.108099
Voir cet article

Design and synthesis of novel N-sulfonyl-2-indoles that behave as 5-HT6 receptor ligands with significant selectivity for D3 over D2 receptors

Oscar M. Saavedra, Delphine Karila, Dominique Brossard, et al.
Bioorganic & Medicinal Chemistry 25 (1) 38 (2017)
DOI: 10.1016/j.bmc.2016.10.010
Voir cet article

Animal Models for the Study of Human Disease

David Feifel and Paul D. Shilling
Animal Models for the Study of Human Disease 587 (2017)
DOI: 10.1016/B978-0-12-809468-6.00023-1
Voir cet article

The atypical antipsychotic blonanserin reverses (+)-PD-128907- and ketamine-induced deficit in executive function in common marmosets

Manato Kotani, Takeshi Enomoto, Takeshi Murai, et al.
Behavioural Brain Research 305 212 (2016)
DOI: 10.1016/j.bbr.2016.02.031
Voir cet article

Targeting the dopamine D3 receptor: an overview of drug design strategies

Antoni Cortés, Estefanía Moreno, Mar Rodríguez-Ruiz, Enric I. Canela and Vicent Casadó
Expert Opinion on Drug Discovery 11 (7) 641 (2016)
DOI: 10.1080/17460441.2016.1185413
Voir cet article

The dopamine D 3 -preferring D 2 /D 3 dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia

David J.G. Watson, Madeleine V. King, Istvan Gyertyán, et al.
European Neuropsychopharmacology 26 (2) 208 (2016)
DOI: 10.1016/j.euroneuro.2015.12.020
Voir cet article

Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases

Samuele Maramai, Sandra Gemma, Simone Brogi, et al.
Frontiers in Neuroscience 10 (2016)
DOI: 10.3389/fnins.2016.00451
Voir cet article

The frontal cortex as a network hub controlling mood and cognition: Probing its neurochemical substrates for improved therapy of psychiatric and neurological disorders

Mark J Millan, Jean-Michel Rivet and Alain Gobert
Journal of Psychopharmacology 30 (11) 1099 (2016)
DOI: 10.1177/0269881116672342
Voir cet article

Novel dimensions of D3 receptor function: Focus on heterodimerisation, transactivation and allosteric modulation

Roberto Maggio, Marco Scarselli, Marta Capannolo and Mark J. Millan
European Neuropsychopharmacology 25 (9) 1470 (2015)
DOI: 10.1016/j.euroneuro.2014.09.016
Voir cet article

On ‘polypharmacy’ and multi-target agents, complementary strategies for improving the treatment of depression: a comparative appraisal

Mark J. Millan
The International Journal of Neuropsychopharmacology 17 (07) 1009 (2014)
DOI: 10.1017/S1461145712001496
Voir cet article

Bart A. Ellenbroek and Andrea M. Cesura
13 1 (2014)
DOI: 10.1007/7355_2014_51
Voir cet article

Negative symptoms of schizophrenia: Clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment

Mark J. Millan, Kevin Fone, Thomas Steckler and William P. Horan
European Neuropsychopharmacology 24 (5) 645 (2014)
DOI: 10.1016/j.euroneuro.2014.03.008
Voir cet article

Dopamine D3 receptor antagonism—still a therapeutic option for the treatment of schizophrenia

Gerhard Gross, Karsten Wicke and Karla U. Drescher
Naunyn-Schmiedeberg's Archives of Pharmacology 386 (2) 155 (2013)
DOI: 10.1007/s00210-012-0806-3
Voir cet article

In Vivo Occupancy of Dopamine D3 Receptors by Antagonists Produces Neurochemical and Behavioral Effects of Potential Relevance to Attention-Deficit–Hyperactivity Disorder

V. Barth, A. B. Need, E. T. Tzavara, et al.
Journal of Pharmacology and Experimental Therapeutics 344 (2) 501 (2013)
DOI: 10.1124/jpet.112.198895
Voir cet article

Towards improved animal models for evaluating social cognition and its disruption in schizophrenia: The CNTRICS initiative

Mark J. Millan and Karen L. Bales
Neuroscience & Biobehavioral Reviews 37 (9) 2166 (2013)
DOI: 10.1016/j.neubiorev.2013.09.012
Voir cet article

Transient and rapid activation of Akt/GSK-3β and mTORC1 signaling by D3 dopamine receptor stimulation in dorsal striatum and nucleus accumbens

Marie-Josèphe Salles, Denis Hervé, Jean-Michel Rivet, et al.
Journal of Neurochemistry 125 (4) 532 (2013)
DOI: 10.1111/jnc.12206
Voir cet article

The potential role of dopamine D3 receptor neurotransmission in cognition

Shinichiro Nakajima, Philip Gerretsen, Hiroyoshi Takeuchi, et al.
European Neuropsychopharmacology 23 (8) 799 (2013)
DOI: 10.1016/j.euroneuro.2013.05.006
Voir cet article

Mathematical modelling of [11C]-(+)-PHNO human competition studies

Graham E. Searle, John D. Beaver, Andri Tziortzi, et al.
NeuroImage 68 119 (2013)
DOI: 10.1016/j.neuroimage.2012.11.033
Voir cet article

Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy

Mark J. Millan, Yves Agid, Martin Brüne, et al.
Nature Reviews Drug Discovery 11 (2) 141 (2012)
DOI: 10.1038/nrd3628
Voir cet article

Blockade of dopamine D3 but not D2 receptors reverses the novel object discrimination impairment produced by post-weaning social isolation: implications for schizophrenia and its treatment

David J. G. Watson, Charles A. Marsden, Mark J. Millan and Kevin C. F. Fone
The International Journal of Neuropsychopharmacology 15 (04) 471 (2012)
DOI: 10.1017/S1461145711000435
Voir cet article

Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents

S Miyamoto, N Miyake, L F Jarskog, W W Fleischhacker and J A Lieberman
Molecular Psychiatry 17 (12) 1206 (2012)
DOI: 10.1038/mp.2012.47
Voir cet article

Novel Antischizophrenia Treatments

Gerhard Gross and Karla Drescher
Handbook of Experimental Pharmacology, Novel Antischizophrenia Treatments 213 167 (2012)
DOI: 10.1007/978-3-642-25758-2_7
Voir cet article

Selective Blockade of Dopamine D3 Receptors Enhances while D2 Receptor Antagonism Impairs Social Novelty Discrimination and Novel Object Recognition in Rats: A Key Role for the Prefrontal Cortex

David JG Watson, Florence Loiseau, Manuela Ingallinesi, et al.
Neuropsychopharmacology 37 (3) 770 (2012)
DOI: 10.1038/npp.2011.254
Voir cet article

Pharmacological or genetic blockade of the dopamine D3 receptor increases cell proliferation in the hippocampus of adult mice

Martin Egeland, Xiaoqun Zhang, Mark J. Millan, Elisabeth Mocaer and Per Svenningsson
Journal of Neurochemistry 123 (5) 811 (2012)
DOI: 10.1111/jnc.12011
Voir cet article

Animal models of schizophrenia

CA Jones, DJG Watson and KCF Fone
British Journal of Pharmacology 164 (4) 1162 (2011)
DOI: 10.1111/j.1476-5381.2011.01386.x
Voir cet article

Influence of social isolation in the rat on serotonergic function and memory – Relevance to models of schizophrenia and the role of 5-HT6 receptors

Charles A. Marsden, Madeleine V. King and Kevin C.F. Fone
Neuropharmacology 61 (3) 400 (2011)
DOI: 10.1016/j.neuropharm.2011.03.003
Voir cet article

Are impairments of time perception in schizophrenia a neglected phenomenon?

Olivier Bonnot, Marie de Montalembert, Solenn Kermarrec, et al.
Journal of Physiology-Paris 105 (4-6) 164 (2011)
DOI: 10.1016/j.jphysparis.2011.07.006
Voir cet article

Imaging Dopamine D3 Receptors in the Human Brain with Positron Emission Tomography, [11C]PHNO, and a Selective D3 Receptor Antagonist

Graham Searle, John D. Beaver, Robert A. Comley, et al.
Biological Psychiatry 68 (4) 392 (2010)
DOI: 10.1016/j.biopsych.2010.04.038
Voir cet article

Current perspectives on selective dopamine D3 receptor antagonists as pharmacotherapeutics for addictions and related disorders

Christian A. Heidbreder and Amy H. Newman
Annals of the New York Academy of Sciences 1187 (1) 4 (2010)
DOI: 10.1111/j.1749-6632.2009.05149.x
Voir cet article

From the cell to the clinic: A comparative review of the partial D2/D3 receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease

Mark J. Millan
Pharmacology & Therapeutics 128 (2) 229 (2010)
DOI: 10.1016/j.pharmthera.2010.06.002
Voir cet article

The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures

Mark J. Millan, Jerry J. Buccafusco, Florence Loiseau, et al.
The International Journal of Neuropsychopharmacology 13 (08) 1035 (2010)
DOI: 10.1017/S1461145710000775
Voir cet article

Modulations of the amide function of the preferential dopamine D3 agonist (R,R)-S32504: Improvements of affinity and selectivity for D3 versus D2 receptors

Jean-Louis Peglion, Christophe Poitevin, Clotilde Mannoury La Cour, Delphine Dupuis and Mark J. Millan
Bioorganic & Medicinal Chemistry Letters 19 (8) 2133 (2009)
DOI: 10.1016/j.bmcl.2009.03.015
Voir cet article

Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs

Mark J. Millan
Neurotherapeutics 6 (1) 53 (2009)
DOI: 10.1016/j.nurt.2008.10.039
Voir cet article

Blockade of dopamine D3 receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: Similar actions of D1 receptor agonists, but not of D2 antagonists

Florence Loiseau and Mark J. Millan
European Neuropsychopharmacology 19 (1) 23 (2009)
DOI: 10.1016/j.euroneuro.2008.07.012
Voir cet article

The preferential dopamine D3 receptor antagonist S33138 inhibits cocaine reward and cocaine-triggered relapse to drug-seeking behavior in rats

Xiao-Qing Peng, Charles R. Ashby, Krista Spiller, et al.
Neuropharmacology 56 (4) 752 (2009)
DOI: 10.1016/j.neuropharm.2008.12.007
Voir cet article